Vaccines (May 2022)

Twelve-Month Longitudinal Serology in SARS-CoV-2 Naïve and Experienced Vaccine Recipients and Unvaccinated COVID-19-Infected Individuals

  • Zion Congrave-Wilson,
  • Wesley A. Cheng,
  • Yesun Lee,
  • Stephanie Perez,
  • Lauren Turner,
  • Carolyn Jennifer Marentes Ruiz,
  • Shirley Mendieta,
  • Adam Skura,
  • Jaycee Jumarang,
  • Jennifer Del Valle,
  • John Kubale,
  • Emma Kaitlynn Allen,
  • Paul G. Thomas,
  • Aubree Gordon,
  • Pia S. Pannaraj

DOI
https://doi.org/10.3390/vaccines10050813
Journal volume & issue
Vol. 10, no. 5
p. 813

Abstract

Read online

Longitudinal data comparing SARS-CoV-2 serology in individuals following infection and vaccination over 12 months are limited. This study compared the magnitude, decay, and variability in serum IgG, IgA, and neutralizing activity induced by natural infection (n = 218) or mRNA vaccination in SARS-CoV-2 naïve (n = 143) or experienced (n = 122) individuals over time using enzyme-linked immunosorbent assays and an in vitro virus neutralization assay. Serological responses were found to be highly variable after natural infection compared with vaccination but durable through 12 months. Antibody levels in vaccinated, SARS-CoV-2 naïve individuals peaked by 1 month then declined through 9 months, culminating in non-detectable SARS-CoV-2-specific serum IgA. Individuals with both infection and vaccination showed SARS-CoV-2-specific IgG and IgA levels that were more robust and slower to decline than the other groups; neutralizing activity remained highest in this group at 9 months past vaccination. These data reinforce the benefit of vaccination after SARS-CoV-2 recovery.

Keywords